IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Amcor plc vs UNITED THERAPEUTICS Corp — Side-by-side quantitative comparison
Based on our 6-factor quantitative model, UNITED THERAPEUTICS Corp (UTHR) is the stronger stock with a composite score of 61.7/100 and a Hold rating, compared to Amcor plc (AMCR) at 58.2/100 (Hold). UTHR ranks #529 in our universe versus #871 for AMCR, giving it an edge of 3.5 points across quality, value, momentum, investment, stability, and short interest factors.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — UTHR leads at 71/100, while AMCR trails at 45/100 (UTHR: 71/100, AMCR: 45/100). The 26-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — UTHR leads at 75/100, while AMCR trails at 60/100 (UTHR: 75/100, AMCR: 60/100). The 15-point gap indicates a meaningful difference in value characteristics between these stocks.
For the Momentum factor — which captures price trends and institutional sentiment over the trailing 3-12 months — AMCR leads at 96/100, while UTHR trails at 64/100 (AMCR: 96/100, UTHR: 64/100). The 32-point gap indicates a meaningful difference in momentum characteristics between these stocks.
For the Investment factor — which assesses capital allocation quality including reinvestment rates and asset growth — UTHR leads at 35/100, while AMCR trails at 19/100 (UTHR: 35/100, AMCR: 19/100). The 16-point gap indicates a meaningful difference in investment characteristics between these stocks.
For the Stability factor — which measures financial health through leverage ratios and price volatility — UTHR leads at 81/100, while AMCR trails at 45/100 (UTHR: 81/100, AMCR: 45/100). The 36-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — AMCR leads at 54/100, while UTHR trails at 43/100 (AMCR: 54/100, UTHR: 43/100). The 11-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, UNITED THERAPEUTICS Corp (UTHR) is utilizing a stronger overall profile than AMCR, with a Composite Score of 62 vs 58. The comparison is extremely close. While UTHR leads slightly on Stability, AMCR remains a competitive alternative.
| Overall Rating | ||
| Composite Score | 62 | 58 |
| Rank | #529 | #871 |
| Stars | 3 / 5 | 3 / 5 |
| Action | Hold | Hold |
| Factor Scores | ||
| Quality | 71 | 45 |
| Value | 75 | 60 |
| Momentum | 64 | 96 |
| Stability | 81 | 45 |
| Investment | 35 | 19 |
| Short Interest | 43 | 54 |
| Valuation | ||
| P/E Ratio | 13.99 | 17.99 |
| P/B Ratio | 2.88 | 1.61 |
| P/S Ratio | 5.93 | 0.82 |
| EV/EBITDA | 11.38 | 5.60 |
| Dividend Yield | 0.0% | 6.2% |
| Profitability | ||
| ROE | 19.1% | 13.3% |
| ROA | 18.3% | 2.9% |
| Gross Margin | 87.4% | 19.6% |
| Operating Margin | 48.6% | 8.0% |
| Net Margin | 42.4% | 4.6% |
| Growth & Risk | ||
| Revenue Growth | 6.8% | 71.3% |
| Debt/Equity | 0.00 | 127.00 |
| Beta | 0.38 | 0.73 |
| Market | ||
| Market Cap | $18.96B | $18.86B |
Based on our 6-factor quantitative model, UTHR currently has the higher composite score (61.7/100, Hold) and ranks #529 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
UTHR has the higher value score at 75/100 compared to AMCR at 60/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.